MA50547A - Composés et compositions d'induction de la chondrogenèse - Google Patents

Composés et compositions d'induction de la chondrogenèse

Info

Publication number
MA50547A
MA50547A MA050547A MA50547A MA50547A MA 50547 A MA50547 A MA 50547A MA 050547 A MA050547 A MA 050547A MA 50547 A MA50547 A MA 50547A MA 50547 A MA50547 A MA 50547A
Authority
MA
Morocco
Prior art keywords
compositions
chondrogenesis induction
induction compounds
compounds
chondrogenesis
Prior art date
Application number
MA050547A
Other languages
English (en)
Inventor
Ha-Soon Choi
Jiqing Jiang
James Paul Lajiness
Bao Nguyen
Hank Michael James Petrassi
Zhicheng Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA50547A publication Critical patent/MA50547A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA050547A 2017-06-09 2018-06-07 Composés et compositions d'induction de la chondrogenèse MA50547A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09

Publications (1)

Publication Number Publication Date
MA50547A true MA50547A (fr) 2020-09-16

Family

ID=62837959

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050547A MA50547A (fr) 2017-06-09 2018-06-07 Composés et compositions d'induction de la chondrogenèse
MA57022A MA57022B1 (fr) 2017-06-09 2018-06-07 Composés et compositions d'induction de la chondrogenèse

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA57022A MA57022B1 (fr) 2017-06-09 2018-06-07 Composés et compositions d'induction de la chondrogenèse

Country Status (37)

Country Link
US (3) US11091499B2 (fr)
EP (3) EP3634967A1 (fr)
JP (2) JP7229945B2 (fr)
KR (1) KR102656524B1 (fr)
CN (1) CN110719913B (fr)
AR (1) AR113227A1 (fr)
AU (1) AU2018279306C1 (fr)
BR (1) BR112019025866A2 (fr)
CA (1) CA3063985A1 (fr)
CL (1) CL2019003564A1 (fr)
CO (1) CO2019013706A2 (fr)
CR (1) CR20190551A (fr)
CU (1) CU24577B1 (fr)
DK (1) DK3915994T3 (fr)
DO (1) DOP2019000305A (fr)
EA (1) EA201992858A1 (fr)
EC (1) ECSP19086712A (fr)
ES (1) ES2971319T3 (fr)
FI (1) FI3915994T3 (fr)
HR (1) HRP20240155T1 (fr)
HU (1) HUE065194T2 (fr)
IL (2) IL300755A (fr)
JO (1) JOP20190282A1 (fr)
LT (1) LT3915994T (fr)
MA (2) MA50547A (fr)
MX (1) MX2019014757A (fr)
PE (1) PE20200403A1 (fr)
PH (1) PH12019502764A1 (fr)
PL (1) PL3915994T3 (fr)
PT (1) PT3915994T (fr)
RS (1) RS65161B1 (fr)
SA (1) SA519410729B1 (fr)
SI (1) SI3915994T1 (fr)
TW (1) TWI782036B (fr)
UY (1) UY37759A (fr)
WO (1) WO2018225009A1 (fr)
ZA (1) ZA201907358B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
EP3891154B1 (fr) * 2018-12-06 2023-08-16 Novartis AG Dérivés de 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide pour l'induction de la chondrogenèse pour le traitement des lésions articulaires
CN113015736B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6407250B1 (en) 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (fr) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Utilisation d'inhibiteurs de kinases pour favoriser la neochondrogenese
US7595327B2 (en) 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
WO2008008884A2 (fr) 2006-07-12 2008-01-17 Cornell Research Foundation, Inc. Inhibition d'agrégation de peptide de bêta-amyloïde
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2757480A1 (fr) 2009-04-02 2010-10-07 Allergan, Inc. Antagonistes du recepteur de la prostaglandine e
KR20160015403A (ko) 2009-07-14 2016-02-12 더 스크립스 리서치 인스티튜트 중간엽 줄기 세포 분화
CA2818903C (fr) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridine-4-yl)pyrimidine-2-amine et son utilisation comme inhibiteur de caseine kinase 1 delta
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (fr) 2011-06-21 2012-12-27 Adispell, Inc. Modification de cognition
WO2013007765A1 (fr) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Composés tricycliques fusionnés utilisés en tant qu'inhibiteurs des janus kinases
KR102283996B1 (ko) * 2013-03-15 2021-07-29 더 스크립스 리서치 인스티튜트 연골형성의 유도를 위한 화합물 및 방법
AU2015259403B2 (en) * 2014-05-13 2017-07-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف

Also Published As

Publication number Publication date
US11753416B2 (en) 2023-09-12
LT3915994T (lt) 2024-02-26
KR102656524B1 (ko) 2024-04-12
IL300755A (en) 2023-04-01
CU24577B1 (es) 2022-02-04
PH12019502764A1 (en) 2020-07-13
MA57022B1 (fr) 2024-02-29
CA3063985A1 (fr) 2018-12-13
HUE065194T2 (hu) 2024-05-28
EP3634967A1 (fr) 2020-04-15
RU2019144107A (ru) 2021-07-09
JP7432778B2 (ja) 2024-02-16
WO2018225009A1 (fr) 2018-12-13
TWI782036B (zh) 2022-11-01
DOP2019000305A (es) 2019-01-15
JP7229945B2 (ja) 2023-02-28
IL271154B2 (en) 2023-07-01
IL271154B1 (en) 2023-03-01
JOP20190282A1 (ar) 2019-12-05
JP2020522550A (ja) 2020-07-30
JP2023062064A (ja) 2023-05-02
CU20190098A7 (es) 2020-10-20
PT3915994T (pt) 2024-02-15
HRP20240155T1 (hr) 2024-04-12
AU2018279306B2 (en) 2020-07-09
ES2971319T3 (es) 2024-06-04
PL3915994T3 (pl) 2024-05-20
US20210079010A1 (en) 2021-03-18
KR20200013046A (ko) 2020-02-05
CN110719913B (zh) 2022-10-28
RU2019144107A3 (fr) 2021-07-30
US20230365580A1 (en) 2023-11-16
US20210347784A1 (en) 2021-11-11
SA519410729B1 (ar) 2022-07-03
CL2019003564A1 (es) 2020-06-19
EP3915994A1 (fr) 2021-12-01
AU2018279306C1 (en) 2021-01-14
MX2019014757A (es) 2020-02-12
FI3915994T3 (fi) 2024-02-14
CO2019013706A2 (es) 2020-04-01
CR20190551A (es) 2020-01-28
ZA201907358B (en) 2022-04-28
RS65161B1 (sr) 2024-02-29
EA201992858A1 (ru) 2020-04-02
EP3915994B1 (fr) 2023-11-22
EP3915994B9 (fr) 2024-02-28
BR112019025866A2 (pt) 2020-07-14
IL271154A (en) 2020-01-30
TW201902900A (zh) 2019-01-16
SI3915994T1 (sl) 2024-03-29
ECSP19086712A (es) 2019-12-27
AU2018279306A1 (en) 2019-12-05
NZ759434A (en) 2024-01-26
UY37759A (es) 2019-01-31
DK3915994T3 (da) 2024-02-19
US11091499B2 (en) 2021-08-17
EP4299123A2 (fr) 2024-01-03
AR113227A1 (es) 2020-02-19
PE20200403A1 (es) 2020-02-26
CN110719913A (zh) 2020-01-21
EP4299123A3 (fr) 2024-04-03

Similar Documents

Publication Publication Date Title
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
MA49421A (fr) Formulations d'arn
MA50269A (fr) Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon
MA43284A (fr) Composés et leurs méthodes d'utilisation
MA49047A (fr) Composés inhibiteurs d'ask1 et utilisations associées
MA51669A (fr) Composés
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA47420A (fr) Composés inhibiteurs d'oga
MA46791A (fr) Composés et procédés pour réduire l'expression d'atxn3
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA54521A (fr) Dérivés d'oxopyridine substitués
FR3033706B3 (fr) Simulateur d'escalier
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
MA51864A (fr) Méthodes d'identification de composés
MA53924A (fr) Modulateurs de l'expression d'apol1
MA46896A (fr) Composés d'alcène tétrasubstitués et leur utilisation
MA49006A (fr) Inhibiteurs d'ip6k
MA46641A (fr) Méthodes et compositions permettant d'empêcher la transmission de maladies propagées par un vecteur
MA50547A (fr) Composés et compositions d'induction de la chondrogenèse
FR3033707B3 (fr) Simulateur d'escalier
MA46431A (fr) Composés et procédés pour réduire l'expression de tau
MA52934A (fr) Composés inhibiteurs de l'oga
MA52946A (fr) Composés
MA50362A (fr) Compositions de désoxygénation colorées ne nécessitant pas de période d'induction
CL2018001505S1 (es) Protector intimo femenino